Author: Steve Kopczak

    • Development of a web-based, theory-guided narrative intervention for women at elevated risk for breast cancer.
    • Katz ML, Senter L, Reiter PL, Emerson B, Ennis AC, Shane-Carson KP, Aeilts A, Cassingham HR, Schnell PM, Agnese DM, Toland AE, Sweet K.
    • Patient Educ Couns. 2022 Oct 29:S0738-3991(22)00820-5. doi: 10.1016/j.pec.2022.10.348. Epub ahead of print.

    • Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
    • Clark NM, Roberts EA, Fedorenko C, Sun Q, Dubard-Gault M, Handford C, Yung R, Cheng HH, Sham JG, Norquist BM, Flanagan MR.
    • Ann Surg Oncol. 2022 Nov 5. doi: 10.1245/s10434-022-12755-y. Epub ahead of print.

    • PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.
    • Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G.
    • Int J Mol Sci. 2022 Oct 25;23(21):12876. doi: 10.3390/ijms232112876.

    • Development of a web-based, theory-guided narrative intervention for women at elevated risk for breast cancer.
    • Katz ML, Senter L, Reiter PL, Emerson B, Ennis AC, Shane-Carson KP, Aeilts A, Cassingham HR, Schnell PM, Agnese DM, Toland AE, Sweet K.
    • Patient Educ Couns. 2022 Oct 29:S0738-3991(22)00820-5. doi: 10.1016/j.pec.2022.10.348. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    • Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI.
    • Ann Surg Oncol. 2022 Nov 5. doi: 10.1245/s10434-022-12681-z. Epub ahead of print.
    • Review

    Related:

    •• Original research:

    Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

    • Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer.
    • Vidula N, Lipman A, Kato S, Weipert C, Hesler K, Azzi G, Elkhanany A, Juric D, Rodriguez E, Faulkner C, Makhlouf P, Price K, O'Shaughnessy J, Bardia A.
    • NPJ Breast Cancer. 2022 Nov 4;8(1):117. doi: 10.1038/s41523-022-00490-2.

    • PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
    • Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Piane CD, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S.
    • Breast. 2022 Oct 29:S0960-9776(22)00179-5. doi: 10.1016/j.breast.2022.10.014. Epub ahead of print.

    • PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?
    • Loguidice CT.
    • OncLive. 2022 Oct 28.

    • PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.
    • Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G.
    • Int J Mol Sci. 2022 Oct 25;23(21):12876. doi: 10.3390/ijms232112876.

    • LitAlert ~~ GeneLit.com

    • ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    • Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI.
    • Ann Surg Oncol. 2022 Nov 5. doi: 10.1245/s10434-022-12681-z. Epub ahead of print.
    • Review

    Related:

    •• Original research:

    Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

    • Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer.
    • Corso G, Girardi A, Calvello M, Gandini S, Gaeta A, Marabelli M, Magnoni F, Veronesi P, Guerrieri-Gonzaga A, Bonanni B.
    • Breast Cancer Res Treat. 2022 Nov 4. doi: 10.1007/s10549-022-06776-0. Epub ahead of print.

    • A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia.
    • Powell M, Fuller S, Gunderson E, Benz C.
    • Breast Cancer Res Treat. 2022 Nov 4. doi: 10.1007/s10549-022-06789-9. Epub ahead of print.

    • Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer.
    • Vidula N, Lipman A, Kato S, Weipert C, Hesler K, Azzi G, Elkhanany A, Juric D, Rodriguez E, Faulkner C, Makhlouf P, Price K, O'Shaughnessy J, Bardia A.
    • NPJ Breast Cancer. 2022 Nov 4;8(1):117. doi: 10.1038/s41523-022-00490-2.

    • Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.
    • Han H, Park CK, Cho NH, Lee J, Jang WS, Ham WS, Choi YD, Cho KS.
    • Int J Mol Sci. 2022 Nov 3;23(21):13426. doi: 10.3390/ijms232113426.

    • PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
    • Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Piane CD, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S.
    • Breast. 2022 Oct 29:S0960-9776(22)00179-5. doi: 10.1016/j.breast.2022.10.014. Epub ahead of print.

    • Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP.
    • Adv Ther. 2022 Oct 28. doi: 10.1007/s12325-022-02302-2. Epub ahead of print.

    • PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?
    • Loguidice CT.
    • OncLive. 2022 Oct 28.

    • Adolescent Triple-negative Breast Cancer with Germline Pathogenic Variants in both BRCA1 and TP53 Genes: A Case Report.
    • Chen D, Yuan M, Zhang Y, Zhang C, Wan D.
    • Front Oncol. 2022 Oct 26;12:970641. doi: 10.3389/fonc.2022.970641.

    • LitAlert ~~ GeneLit.com

    • Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
    • Clark NM, Roberts EA, Fedorenko C, Sun Q, Dubard-Gault M, Handford C, Yung R, Cheng HH, Sham JG, Norquist BM, Flanagan MR.
    • Ann Surg Oncol. 2022 Nov 5. doi: 10.1245/s10434-022-12755-y. Epub ahead of print.

    • Development of a web-based, theory-guided narrative intervention for women at elevated risk for breast cancer.
    • Katz ML, Senter L, Reiter PL, Emerson B, Ennis AC, Shane-Carson KP, Aeilts A, Cassingham HR, Schnell PM, Agnese DM, Toland AE, Sweet K.
    • Patient Educ Couns. 2022 Oct 29:S0738-3991(22)00820-5. doi: 10.1016/j.pec.2022.10.348. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer.
    • Corso G, Girardi A, Calvello M, Gandini S, Gaeta A, Marabelli M, Magnoni F, Veronesi P, Guerrieri-Gonzaga A, Bonanni B.
    • Breast Cancer Res Treat. 2022 Nov 4. doi: 10.1007/s10549-022-06776-0. Epub ahead of print.

    • A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia.
    • Powell M, Fuller S, Gunderson E, Benz C.
    • Breast Cancer Res Treat. 2022 Nov 4. doi: 10.1007/s10549-022-06789-9. Epub ahead of print.

    • Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer.
    • Vidula N, Lipman A, Kato S, Weipert C, Hesler K, Azzi G, Elkhanany A, Juric D, Rodriguez E, Faulkner C, Makhlouf P, Price K, O'Shaughnessy J, Bardia A.
    • NPJ Breast Cancer. 2022 Nov 4;8(1):117. doi: 10.1038/s41523-022-00490-2.

    • Adolescent Triple-negative Breast Cancer with Germline Pathogenic Variants in both BRCA1 and TP53 Genes: A Case Report.
    • Chen D, Yuan M, Zhang Y, Zhang C, Wan D.
    • Front Oncol. 2022 Oct 26;12:970641. doi: 10.3389/fonc.2022.970641.

    • PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.
    • Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G.
    • Int J Mol Sci. 2022 Oct 25;23(21):12876. doi: 10.3390/ijms232112876.